Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis: a Multicenter Randomized Controlled Non-inferiority Study (RIFREE)

NCT07345325 Phase 3 NOT_YET_RECRUITING

The primary objective of this study is to demonstrate that a rifampin-free regimen is non-inferior to the rifampin-containing regimen in terms of all-cause mortality in staphylococcal prosthetic valve endocarditis within 6 months after randomization.

Details

Lead sponsor	Nantes University Hospital
Phase	Phase 3
Status	NOT_YET_RECRUITING
Enrolment	422
Start date	2026-01
Completion	2031-01

Conditions

• Infective Endocarditis

Interventions

• Rifampin-free regimen
• Rifampin containing regimen

Primary outcomes

• All-cause mortality rate at 6 months — Up to 6 months
  Deaths of all causes from randomizaton until 6 months

Countries

France